These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38173721)

  • 1. Light-enhanced VEGF
    Longva AS; Berg K; Weyergang A
    Front Immunol; 2023; 14():1278000. PubMed ID: 38173721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Light-enhanced VEGF
    Weyergang A; Fremstedal AS; Skarpen E; Peng Q; Mohamedali KA; Eng MS; Cheung LH; Rosenblum MG; Waltenberger J; Berg K
    J Control Release; 2018 Oct; 288():161-172. PubMed ID: 30217739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Photochemical internalization augments tumor vascular cytotoxicity and specificity of VEGF(121)/rGel fusion toxin.
    Weyergang A; Cheung LH; Rosenblum MG; Mohamedali KA; Peng Q; Waltenberger J; Berg K
    J Control Release; 2014 Apr; 180():1-9. PubMed ID: 24531010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corrigendum: Light-enhanced VEGF
    Longva AS; Berg K; Weyergang A
    Front Immunol; 2023; 14():1359973. PubMed ID: 38264651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors.
    Mohamedali KA; Kedar D; Sweeney P; Kamat A; Davis DW; Eve BY; Huang S; Thorpe PE; Dinney CP; Rosenblum MG
    Neoplasia; 2005 Oct; 7(10):912-20. PubMed ID: 16242074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Photochemical activation of the recombinant HER2-targeted fusion toxin MH3-B1/rGel; Impact of HER2 expression on treatment outcome.
    Bull-Hansen B; Cao Y; Berg K; Skarpen E; Rosenblum MG; Weyergang A
    J Control Release; 2014 May; 182():58-66. PubMed ID: 24637464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of an EGFR-targeting toxin for photochemical delivery: in vitro and in vivo selectivity and efficacy.
    Berstad MB; Cheung LH; Berg K; Peng Q; Fremstedal AS; Patzke S; Rosenblum MG; Weyergang A
    Oncogene; 2015 Oct; 34(44):5582-92. PubMed ID: 25684137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Photochemical activation of MH3-B1/rGel: a HER2-targeted treatment approach for ovarian cancer.
    Bull-Hansen B; Berstad MB; Berg K; Cao Y; Skarpen E; Fremstedal AS; Rosenblum MG; Peng Q; Weyergang A
    Oncotarget; 2015 May; 6(14):12436-51. PubMed ID: 26002552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-modality therapeutics with potent anti-tumor effects: photochemical internalization enhances delivery of the fusion toxin scFvMEL/rGel.
    Selbo PK; Rosenblum MG; Cheung LH; Zhang W; Berg K
    PLoS One; 2009 Aug; 4(8):e6691. PubMed ID: 19690617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitive angiogenesis imaging of orthotopic bladder tumors in mice using a selective magnetic resonance imaging contrast agent containing VEGF121/rGel.
    Cho EJ; Yang J; Mohamedali KA; Lim EK; Kim EJ; Farhangfar CJ; Suh JS; Haam S; Rosenblum MG; Huh YM
    Invest Radiol; 2011 Jul; 46(7):441-9. PubMed ID: 21512397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice.
    Chen JS; Hsieh YC; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel.
    Mohamedali KA; Poblenz AT; Sikes CR; Navone NM; Thorpe PE; Darnay BG; Rosenblum MG
    Cancer Res; 2006 Nov; 66(22):10919-28. PubMed ID: 17108129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenic cell death due to a new photodynamic therapy (PDT) with glycoconjugated chlorin (G-chlorin).
    Tanaka M; Kataoka H; Yano S; Sawada T; Akashi H; Inoue M; Suzuki S; Inagaki Y; Hayashi N; Nishie H; Shimura T; Mizoshita T; Mori Y; Kubota E; Tanida S; Takahashi S; Joh T
    Oncotarget; 2016 Jul; 7(30):47242-47251. PubMed ID: 27363018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel.
    Hsu AR; Cai W; Veeravagu A; Mohamedali KA; Chen K; Kim S; Vogel H; Hou LC; Tse V; Rosenblum MG; Chen X
    J Nucl Med; 2007 Mar; 48(3):445-54. PubMed ID: 17332623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.
    Mohamedali KA; Li ZG; Starbuck MW; Wan X; Yang J; Kim S; Zhang W; Rosenblum MG; Navone NM
    Clin Cancer Res; 2011 Apr; 17(8):2328-38. PubMed ID: 21343372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. M1-derived extracellular vesicles enhance photodynamic therapy and promote immunological memory in preclinical models of colon cancer.
    Huis In 't Veld RV; Lara P; Jager MJ; Koning RI; Ossendorp F; Cruz LJ
    J Nanobiotechnology; 2022 Jun; 20(1):252. PubMed ID: 35658868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translocator protein-targeted photodynamic therapy for direct and abscopal immunogenic cell death in colorectal cancer.
    Xie Q; Li Z; Liu Y; Zhang D; Su M; Niitsu H; Lu Y; Coffey RJ; Bai M
    Acta Biomater; 2021 Oct; 134():716-729. PubMed ID: 34329783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low dose hypericin-PDT induces complete tumor regression in BALB/c mice bearing CT26 colon carcinoma.
    Sanovic R; Verwanger T; Hartl A; Krammer B
    Photodiagnosis Photodyn Ther; 2011 Dec; 8(4):291-6. PubMed ID: 22122915
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.